The third-generation CAR is based on the second-generation with the addition of a co-stimulatory molecule, mainly CD28 and CD137; it confers stronger cytokine release and tumor-killing ability, but is also prone to promoting the phenomenon of activation-induced cell death. Here, TNFRSF9 is linked to neoplasm.